Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial [0.03%]
将新型优化心脏再同步治疗算法的经济影响：AdaptResponse试验的经济分析rationale和设计
Gerasimos Filippatos,Xiaoxiao Lu,Stelios I Tsintzos et al.
Gerasimos Filippatos et al.
Aims: Although cardiac resynchronization therapy (CRT) has proven beneficial in several randomized trials, a subset of patients have limited clinical improvement. The AdaptivCRT algorithm provides automated selection betw...
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641-649 [0.03%]
关于Wu JJ, Hansen JB, Patel DS等人的研究《钙泊三醇0.005%/二丙酸倍他米松0.064%泡沫与卤obetasol 0.01%/他扎罗汀0.045%乳液治疗斑块型银屑病的有效性比较及增量成本-反应者分析：一项匹配调整的间接对比分析》（J Med Econ. 2020;23(6):641-649）的回复
Brad Glick,Annie Guerin,Rajeev Ayyagari et al.
Brad Glick et al.
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641-649 [0.03%]
评论：关于钙泊三醇0.005%/二丙酸倍他米松0.064%泡沫与卤米松0.01%/塔扎罗汀0.045%乳液治疗斑块型银屑病的效果对比及增量成本-反应者分析的匹配调整间接比较分析的回复。J Med Econ. 2020;23(6):641-649
Jashin J Wu,Jes B Hansen,Dharm S Patel et al.
Jashin J Wu et al.
Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis [0.03%]
西班牙成骨不全的医院发病率、处理和直接成本的回顾性数据库分析
Josep Darbà,Alicia Marsà
Josep Darbà
Objective: The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective. ...
Multicenter Study
Journal of medical economics. 2020 Dec;23(12):1435-1440. DOI:10.1080/13696998.2020.1834402 2020
Cristian Martignani,Giulia Massaro,Igor Diemberger et al.
Cristian Martignani et al.
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv [0.03%]
化疗引起的(发热)中性粒细胞减少症的预防治疗的成本效益和扩大访问：从参考培非格司亭转换为生物类似培非格司亭_cbqv的美国经济模拟分析
Karen MacDonald,Ali McBride,Neda Alrawashdh et al.
Karen MacDonald et al.
Aims: In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced (febrile) neutrop...
Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA [0.03%]
美国住院房颤患者的抗凝治疗及影响治疗的因素分析
Steven Deitelzweig,Amol D Dhamane,Manuela Di Fusco et al.
Steven Deitelzweig et al.
Objective: To evaluate utilization of anticoagulants (ACs) and the predictors of treatment of patients with a diagnosis of atrial fibrillation (AF) during a hospital stay in the USA. ...
Economic burden of subsequent fracture in osteoporosis patients in South Korea [0.03%]
韩国骨质疏松患者后续骨折的经济负担
Jae-A Park,Jin Hyun Nam,Sung-Hyun Hong et al.
Jae-A Park et al.
Objectives: This study aimed to assess the economic burden of subsequent fracture in osteoporosis patients with incident fracture. Methods: ...
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome [0.03%]
拉卢利珠单抗与埃库利珠单抗用于治疗非典型溶血性尿毒症综合症的美国成本最小化模型比较
Yan Wang,Karissa Johnston,Evan Popoff et al.
Yan Wang et al.
Aims: Ravulizumab, engineered from eculizumab, provides sustained C5 inhibition in atypical hemolytic uremic syndrome (aHUS) while reducing dosing frequency (every 8 vs 2 weeks, respectively). Treatment choice often carri...
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan [0.03%]
日本晚期黑色素瘤一线治疗中nivolumab联合ipilimumab的经济评估
Victoria Federico Paly,Yusuke Hikichi,Timothy Baker et al.
Victoria Federico Paly et al.
Aims: The objective of this study was to evaluate the cost-effectiveness of nivolumab in combination with ipilimumab (nivo + ipi) compared to current therapeutic alternatives in first-line treatment of patients with advan...